{"protocolSection":{"identificationModule":{"nctId":"NCT04077814","orgStudyIdInfo":{"id":"tDCS_FDS_2018"},"organization":{"fullName":"Federal University of Health Science of Porto Alegre","class":"OTHER"},"briefTitle":"Association Between the tDCS and FDS for Gait Rehabilitation After Stroke","officialTitle":"Association Between the Transcranial Direct Current Stimulation (tDCS) and Foot Drop Stimulation (FDS) for Gait Rehabilitation After Stroke - A Randomized Clinical Trial"},"statusModule":{"statusVerifiedDate":"2021-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-09-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-09-20","type":"ACTUAL"},"completionDateStruct":{"date":"2020-09-30","type":"ACTUAL"},"studyFirstSubmitDate":"2019-06-12","studyFirstSubmitQcDate":"2019-08-31","studyFirstPostDateStruct":{"date":"2019-09-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-02-10","lastUpdatePostDateStruct":{"date":"2021-02-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Aline de Souza Pagnussat","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Federal University of Health Science of Porto Alegre"},"leadSponsor":{"name":"Federal University of Health Science of Porto Alegre","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The aim of this study is to verify the effectiveness of tDCS combined with foot drop stimulation (FDS) on gait rehabilitation of post-stroke subjects with mild and moderate compromise."},"conditionsModule":{"conditions":["Stroke"],"keywords":["Cerebrovascular Accident","Cerebrovascular Stroke","Cerebral Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":40,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"ShamtDCS+FDS","type":"ACTIVE_COMPARATOR","description":"Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Sham Transcranial direct brain stimulation (tDCS)","interventionNames":["Device: Foot Drop Stimulatio - Neuro Orthosis"]},{"label":"tDCS+FDS","type":"EXPERIMENTAL","description":"Chronic stroke patients submitted to Foot Drop Stimulation (FDS) + Transcranial direct brain stimulation (tDCS)","interventionNames":["Device: Foot Drop Stimulatio - Neuro Orthosis","Device: Transcranial direct brain stimulation"]}],"interventions":[{"type":"DEVICE","name":"Foot Drop Stimulatio - Neuro Orthosis","description":"Walkaide is the Foot drop stimulator (FDS) on the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.","armGroupLabels":["ShamtDCS+FDS","tDCS+FDS"]},{"type":"DEVICE","name":"Transcranial direct brain stimulation","description":"Transcranial direct brain stimulation on motor cortex","armGroupLabels":["tDCS+FDS"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Kinematic gait anaysis.","description":"Evaluated by means of the 3-D motion analysis system (BTS SMART DX 400)","timeFrame":"The outcome will assess at baseline and two weeks after the intervention. One month later that finished the intensive treatment subjects will re-evaluate."}],"secondaryOutcomes":[{"measure":"Kinetic gait anaysis.","description":"Assessed by force platform (BTS P-6000)","timeFrame":"The outcome will assess at baseline and two weeks after the intervention. One month later that finished the intensive treatment subjects will re-evaluate."},{"measure":"Postural Control","description":"Evaluated by Center of Pressure (COP) displacement assessed on force platform (BTS P-6000)","timeFrame":"The outcome will assess at baseline and two weeks after the intervention. One month later that finished the intensive treatment subjects will re-evaluate."},{"measure":"Functional Mobility","description":"Evaluated by means of the Timed Up \\& Go Test (TUG)","timeFrame":"The outcome will assess at baseline and two weeks after the intervention. One month later that finished the intensive treatment subjects will re-evaluate."},{"measure":"Assessed by means of the Stroke-Specific Quality of Life Questionnaire (SSQOL)","description":"The SSQOL questionnaire assesses the quality of life of stroke subject, and it contains 49 items with 12 domains (energy, family role, language, mobility, mood, personality, self-care, social role, reasoning, upper limb function, vision and work/productivity). There are three possible answers on the 5-point Likert scale.\n\nThe SSOOL questionnaire score reports a minimum of 49 points and a maximum of 245 points. The lower values represent the more dependence and difficulty to perform tasks.","timeFrame":"The outcome will assess at baseline and two weeks after the intervention. One month later that finished the intensive treatment subjects will re-evaluate."},{"measure":"Muscular tone assessed by the Modified Ashworth Scale","description":"Assessed by the Modified Ashworth Scale. This scale consists of 5 ordinal values ranging from 0 (no tonus increase) to 4 (stiffness).","timeFrame":"The outcome will assess at baseline and two weeks after the intervention. One month later that finished the intensive treatment subjects will re-evaluate."},{"measure":"Assessment of Sensorimotor Recovery After Stroke by Fugl-Meyer scale","description":"Fugl-Meyer scale of lower limb impairment. The evaluation includes measurement of voluntary movement, velocity, coordination and reflex activity, through an ordinal scale applied to each item: 0- cannot be performed, 1- partially performed, and 2-performed completely. Participants were also classified according their LL motor impairment in severe (0 to19), moderate (20 to 28) or mild (\\> 29 points).","timeFrame":"The outcome will assess at baseline and two weeks after the intervention. One month later that finished the intensive treatment subjects will re-evaluate."},{"measure":"Serum levels of Brain-derived neurotrophic fator (BDNF).","description":"The biomarker BDNF will be determined using the enzyme-linked immunosorbent assay (ELISA) method.","timeFrame":"The outcome will be assessed at baseline and 2 weeks after the intervention."},{"measure":"Serum levels of Insulin-like growth factor binding protein-3 (IGFBP-3)","description":"The biomarker IGFBP-3 will be analyzed in the blood sample to evaluate the neuromuscular adaptations indirectly. Serum IGFBP-3 levels will be determined using the enzyme-linked immunosorbent assay (ELISA) method.","timeFrame":"The outcome will be assessed at baseline and 2 weeks after the intervention."},{"measure":"Serum levels of insulin-like growth factors 1 (IGF-1)","description":"The IGF-1 will be analyzed in the blood sample to evaluate the neuromuscular adaptations indirectly. Serum IGF-1 levels will be determined using the enzyme-linked immunosorbent assay (ELISA) method.","timeFrame":"The outcome will be assessed at baseline and 2 weeks after the intervention."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with ischemic or hemorrhagic stroke diagnosis.\n* Mild, moderate or severe hemiparesis (chronic stroke - at least 6 months)\n* Minimal cognitive ability to understand commands\n* Able to walk 10 meters unassisted or with minimal assistance\n\nExclusion Criteria:\n\n* No current use of antiepileptic drugs for seizures\n* Secondary musculoskeletal disorder involving the lower limb\n* Contraindication for electrical stimulation","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Aline S Pagnussat, PhD","affiliation":"Federal University of Health Sciences of Porto Alegre","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Federal University of Health Sciences of Porto Alegre","city":"Porto Alegre","state":"Rio Grande Do Sul","country":"Brazil","geoPoint":{"lat":-30.03306,"lon":-51.23}}]},"referencesModule":{"references":[{"pmid":"35689805","type":"DERIVED","citation":"da Cunha MJ, Pinto C, Schifino GP, Sant'Anna Py I, Cimolin V, Pagnussat AS. Bicephalic Transcranial Direct-Current Stimulation Does Not Add Benefits to a Footdrop Stimulator for Improving Functional Mobility in People With Chronic Hemiparesis After Stroke: A Double-Blind, Randomized Controlled Trial. Phys Ther. 2022 Aug 4;102(8):pzac079. doi: 10.1093/ptj/pzac079."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false}